A practical guide to the interpretation of PK/PD profiles of longer-acting analogue insulins. Part two: Insulin degludec vs. insulin glargine U300

Figures & data

Figure 1: Diurnal fluctuations in the glucodynamics of IDeg⁹ and Gla-300.¹²

Notes: The glucose clamp studies were performed at a steady-state of IDeg and Gla-300. A dose of 0.4 IU/kg was used for both longer-acting basal analogue insulins.

Table 1: Comparison of published glucose clamp results of insulin degludec (IDeg) and insulin glargine U300 (Gla-300)

Factor	Insulin degludec	Insulin glargine 300
Clamp methodology	Biostator^7,8	Biostator^12
Duration of clamp study	24 h^8	24 h^12
	26 h^7	36 h^5,10,11
	42 h^9
Study population	Type 1 DM^8,9	Type 1 DM^5,10–12
	Type 2 DM^7
Dose of study insulin	0.4, 0.6, 0.8 IU/kg^7–9	0.4, 0.6, 0.9 IU/kg/day^5,10–12
Steady state	Yes^7–9	Yes^5,10,12
		No^11
Maximum plasma insulin concentration (study insulin at 0.4 IU/kg)	Approx. 833.3 μU/ml^9	15 μU/ml^10,12
		10.9 and 8.9 μU/ml^11

Heise T , Hövelmann U , Nosek L , et al . Comparison of the pharmacokinetic and pharmacodynamics profiles of insulin degludec and insulin glargine. Expert Opin Drug Metab Toxicol. 2015;11(8): 1193–1201.10.1517/17425255.2015.1058779

 PubMed Web of Science ®Google Scholar

Becker RHA , Nowotny I , Teichert L , et al . Low within- and between-day variability in exposure to new insulin glargine 300 U/ml. Diabetes Obes Metab. 2015;17: 261–7.10.1111/dom.2015.17.issue-3

 PubMed Web of Science ®Google Scholar

Heise T , Hermanski L , Nosek L , et al . Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14: 859–864.10.1111/dom.2012.14.issue-9

 PubMed Web of Science ®Google Scholar

Heise T , Nosek L . Bottcher SG, at al. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012;14: 944–950.10.1111/dom.2012.14.issue-10

 PubMed Web of Science ®Google Scholar

Shiramoto M , Eto T , Irie S , et al . Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes. Diabetes Obes Metab. 2015;17: 254–60.10.1111/dom.2015.17.issue-3

 PubMed Web of Science ®Google Scholar